Active	Status	Sponsor type	Region	Phase	Filter
4 Active 6 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Dong-Wook
NCT03459534: A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs	Recruiting	3	173	RoW	Radotinib HCl, SUPECT	Il-Yang Pharm. Co., Ltd.	Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome	06/26	12/27
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies	Active, not recruiting	1/2	122	Europe, US, RoW	Vodobatinib (K0706) capsules	Sun Pharma Advanced Research Company Limited	Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)	08/26	08/26
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia	Recruiting	1	180	Europe, Canada, US, RoW	ELVN-001	Enliven Therapeutics	Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml	12/26	12/26
NCT04150471: Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients	Recruiting	N/A	79	RoW	RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis	Seoul St. Mary's Hospital, Bristol-Myers Squibb	Chronic Myelocytic Leukemia	12/20	12/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Dong-Wook
NCT03459534: A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs	Recruiting	3	173	RoW	Radotinib HCl, SUPECT	Il-Yang Pharm. Co., Ltd.	Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome	06/26	12/27
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies	Active, not recruiting	1/2	122	Europe, US, RoW	Vodobatinib (K0706) capsules	Sun Pharma Advanced Research Company Limited	Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)	08/26	08/26
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia	Recruiting	1	180	Europe, Canada, US, RoW	ELVN-001	Enliven Therapeutics	Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml	12/26	12/26
NCT04150471: Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients	Recruiting	N/A	79	RoW	RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis	Seoul St. Mary's Hospital, Bristol-Myers Squibb	Chronic Myelocytic Leukemia	12/20	12/23